SCHEMBL2632438

SCHEMBL2632438

COc1cc(CCOC(=N)C(Cl)(Cl)Cl)ccc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.38
TAAR1 Q96RJ0 2/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 1/20 0.38
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 2/20 0.36
KDM4E B2RXH2 1/20 0.36
APP P05067 1/20 0.36
AKR1B1 P15121 1/20 0.36
PTPN1 P18031 1/20 0.36
ALOX5 P09917 2/20 0.36
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2632620 0.89 CHRM5 (0.42) METTSHRMAPK1MAPTLMNA
SCHEMBL1323237 0.89 MAPT (0.49) MAPTKMT2AATMKDM4EAPP
SCHEMBL2632435 0.85 CNR1 (0.35) KMT2AAPP
SCHEMBL16481554 0.83 CYP1A2 (0.54) METTSHRLMNAKMT2AAPP
SCHEMBL12296002 0.83 MAPT (0.44) MAPTKMT2AATMKDM4EAPP
SCHEMBL12295983 0.83 MAPT (0.44) MAPTKMT2AATMKDM4EAPP
SCHEMBL12328264 0.81 SIGMAR1 (0.46)
SCHEMBL12327945 0.81 HDAC1 (0.45) GLAKMT2A
SCHEMBL10207930 0.81 STAT3 (0.38) METTAAR1TSHRMAPK1LMNA
SCHEMBL12296014 0.80 MAPT (0.40) MAPTLMNAKMT2AATMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115081-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2015-08-25 US disclosed
US-8692002-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2014-04-08 US disclosed
US-20130102791-A1 SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP. (CA) 2013-04-25 US disclosed
US-8163938-B2 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2012-04-24 US disclosed
US-20110004006-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2011-01-06 US disclosed
US-7767830-B2 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2010-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110004006-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF KCNH2, KCNC1, KCNH3 MET 4715/4885TAAR1 820/4885TSHR 3782/4885
US-20130102791-A1 SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS DDC, PAICS, CYP4F2 MET 1818/4885TAAR1 111/4885TSHR 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.